Aakash Desai, Associate Director of Phase 1 and Precision Oncology Program at UAB O’Neal Comprehensive Cancer Center, shared posts on X:
“My top 7 thoracic picks for ESMO26, ranked.
5 of these phase 3s already announced positive toplines. ESMO is where we finally see effect sizes. The question each one answers.
SAFFRON (LBA6), Oct 25, 16:54 CET
Osimertinib + savolitinib vs platinum-pemetrexed, EGFRm MET-high NSCLC after osimertinib. Sponsors report PFS + OS wins.
How big, and which MET IHC/FISH cutoff selects patients?
DeLLphi-305 (LBA3), Oct 24, 17:18 CEST
Tarlatamab + durvalumab as 1L maintenance in ES-SCLC. Amgen reports an OS win at interim.
How large, and can clinics deliver T-cell engager monitoring in maintenance?
Krascendo 1 (LBA5), Oct 25, 16:30 CET
Divarasib vs sotorasib or adagrasib, pretreated KRAS G12C NSCLC. Roche reports PFS + OS wins.
How wide is the gap within the G12C class, and at what tolerability?
OptiTROP-Lung06 (LBA66), Oct 25, 10:53 CET
Sac-TMT + pembro vs chemo + pembro, 1L PD-L1-negative nonsquamous NSCLC. PFS met per Kelun-Biotech.
Can a TROP2 ADC replace the platinum doublet alongside IO?
PANKU-Lung01 (LBA71), Oct 26, 09:14 CET
Iza-bren (EGFR×HER3 bispecific ADC) vs platinum-pemetrexed after 3rd-gen EGFR TKI. Interim PFS met per Sichuan Biokin.
First effect sizes: how big, and at what toxicity?
Early-phase ADCs: ABBV-706 (3837RO), Oct 26, 10:15 CET
SEZ6 ADC in relapsed SCLC. Where does it fit next to DLL3 and B7-H3? Temab-A (2658RO, Oct 24, 09:27 CEST), c-Met ADC, phase 1 OS in NSQ NSCLC.
Does c-Met level select who benefits?
Full cards in the graphic.
What’s on your ESMO26 lung list that I missed?”
You can also read: What Changes in Lung Oncology After ESMO 2026? Survival Breakthroughs, ADC Competition, and a New Era of Precision Treatment.
